ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 610

Disease Specific Quality Of Life Domains Are Impaired In Patients With Lupus Nephritis?

Meenakshi Jolly1, Zineb Aouhab2, Sergio Toloza3, Ana M. Bertoli4, Ivana Blazevik5, Luis M. Vila6, Ioana Moldovan7, Karina Marianne D. Torralba8, Arif Kaya9, Berna Goker10, Mehmet E. Tezcan11, Seminur Haznedaroglu12, Josiane Bourré-Tessier13, Ann E. Clarke14, D.J. Wallace15, Michael H. Weisman16 and Graciela S. Alarcon17, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Medicine, John H Stroger Hospital, Chicago, IL, 3Hospital San Juan Bautista, Catamarca, Argentina, 4Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, 5University of Buenos Aires, Buenos Aries, Argentina, 6Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 7Loma Linda Univ Medical Center, Loma Linda, CA, 8Rheumatology/Int Med, USC Keck Schl of Medicine, Los Angeles, CA, 9Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 10Internal Medicine-Rheumatology, Gazi University, Ankara, Turkey, 11Rheumatology, Dr. Lutfi Kirdar Kartal EA Hastanesi, Istanbul, Turkey, 12Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, 13Rheumatology, McGill University, Montréal, QC, Canada, 14Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 15Cedars-Sinai Medical Center, Los Angeles, CA, 16Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 17Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: lupus nephritis and quality of life, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Often systemic Lupus Erythematosus (SLE) patients with Lupus Nephritis (LN) require frequent visits with their health care providers, follow up, and exposure to immunosuppressive medications with potential for significant side effects (e.g. fertility). Thus far, studies have not examined the adverse effects of LN using a disease specific patient reported outcome tool, which can address these concerns. Herein, we compare quality of life (QOL) in patients with and without history of LN using a disease specific quality of life (QOL) questionnaire-LupusPRO.

Methods:  

791 SLE patients from North and South America, the Philippines and Turkey completed LupusPRO, which has 12 domains involving health-related quality of life (HRQOL) and non-health related quality of life (N-HRQOL) construct in 33 questions (Domain scores range 0-100; Hi=Better QOL).  Health outcomes including Physician Global Assessment (PGA), Systemic Lupus Erythematous Disease Activity Index (SELENA-SLEDAI) and the SLICC Damage Index were physician-assessed cross-sectionally. Rheumatologists indicated on the ACR criteria if patients had a history of LN (irrespective of current activity). These patient and physician outcomes were compared using Chi square and non parametric statistical tests; p value of ≤ 0.05 was considered significant.

Results:

304/ 791 SLE patients had LN.  Renal biopsy results were available on 184/304 LN patients: 7 LN-WHO Class I; 25-LN Class II; 120 LN Class III or IV or combinations; 29 LN-Class V; 3 LN-Class VI. Demographic, physician assessed and patient reported outcomes are shown in Table 1.

LN patients were younger, had greater disease activity and damage, were more often and on greater dose of prednisone, more often on mycophenolate-mofetil, and reported poorer health outcomes than SLE patients without LN, in both the HRQOL (Lupus medications, procreation, and emotional health) and the NHRQOL (Desires-Goals) constructs.

Conclusion:

LN patients have worse physician and patient reported health outcomes than those without LN. They voiced concerns on several areas (concerns about lupus medications side effects, procreation, emotional health and effects on their personal goals and aspirations), which can be easily assessed with LupusPro.

Table 1: Comparison of health outcomes by Lupus Nephritis Status


Disclosure:

M. Jolly,

GSK,

5,

GSK,

5,

Medimmune,

5,

Medimmune,

5;

Z. Aouhab,
None;

S. Toloza,
None;

A. M. Bertoli,
None;

I. Blazevik,
None;

L. M. Vila,
None;

I. Moldovan,
None;

K. M. D. Torralba,
None;

A. Kaya,
None;

B. Goker,
None;

M. E. Tezcan,
None;

S. Haznedaroglu,
None;

J. Bourré-Tessier,
None;

A. E. Clarke,
None;

D. J. Wallace,
None;

M. H. Weisman,
None;

G. S. Alarcon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-specific-quality-of-life-domains-are-impaired-in-patients-with-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology